Expand LLY Menu
LLY MENU

LLY Latest Press Releases

-- September 25, 2024 --

New data show Lilly's EBGLYSS (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

-- September 24, 2024 --

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse Globe Newswire 8:45 AM
Lilly's Kisunla (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 6:00 AM

-- September 13, 2024 --

FDA Approves Lilly's EBGLYSS (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis PRNewswire 4:08 PM

-- September 12, 2024 --

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment PRNewswire 5:30 AM

-- September 10, 2024 --

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes PRNewswire 11:57 AM
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes PRNewswire 11:18 AM

-- September 9, 2024 --

Lilly appoints Lucas Montarce as executive vice president and chief financial officer PRNewswire 6:45 AM

-- September 5, 2024 --

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin PRNewswire 6:45 AM

-- September 4, 2024 --

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries PRNewswire 6:00 AM

-- August 27, 2024 --

Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity PRNewswire 6:45 AM

-- August 22, 2024 --

Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference PRNewswire 10:00 AM

-- August 20, 2024 --

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight PRNewswire 6:45 AM

-- August 16, 2024 --

Lilly announces retirement of Marschall S. Runge from its Board of Directors PRNewswire 4:15 PM
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease PRNewswire 8:39 AM

-- August 13, 2024 --

Lilly opens state-of-the-art research and development center in the Boston Seaport PRNewswire 8:00 AM

-- August 8, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion PRNewswire 6:45 AM

-- August 6, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 4:00 PM
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 Globe Newswire 8:30 AM

-- August 2, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM

-- August 1, 2024 --

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity PRNewswire 6:45 AM

-- July 29, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 4:00 PM

-- July 28, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM

-- July 25, 2024 --

Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PRNewswire 10:00 AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected Globe Newswire 8:30 AM

-- July 19, 2024 --

MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF Business Wire 5:59 PM

-- July 9, 2024 --

MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF Business Wire 5:32 PM

-- July 8, 2024 --

GordonMD Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly Business Wire 8:15 AM
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease PRNewswire 6:45 AM

-- July 2, 2024 --

Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 1:35 PM

-- June 25, 2024 --

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria PRNewswire 10:00 AM

-- June 24, 2024 --

Lilly Declares Third-Quarter 2024 Dividend PRNewswire 11:30 AM

-- June 21, 2024 --

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution PRNewswire 3:50 PM

-- June 11, 2024 --

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises Globe Newswire 8:45 AM

-- June 8, 2024 --

Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks PRNewswire 9:03 AM

-- June 5, 2024 --

Lilly announces departure of Anat Ashkenazi, chief financial officer PRNewswire 7:45 AM

-- June 4, 2024 --

Melissa Seymour to join Lilly as executive vice president of Global Quality PRNewswire 9:00 AM

-- June 1, 2024 --

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO Annual Meeting PRNewswire 8:00 AM

-- May 29, 2024 --

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases PRNewswire 6:00 AM

-- May 28, 2024 --

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference PRNewswire 10:00 AM

-- May 24, 2024 --

Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District Globe Newswire 9:34 AM
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines PRNewswire 9:30 AM

-- May 23, 2024 --

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PRNewswire 5:00 PM

-- May 21, 2024 --

More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure PRNewswire 8:00 AM

-- May 16, 2024 --

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin PRNewswire 6:45 AM

-- May 15, 2024 --

Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer PRNewswire 8:00 AM

-- May 6, 2024 --

Lilly Declares Second-Quarter 2024 Dividend PRNewswire 11:32 AM

-- April 30, 2024 --

Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum PRNewswire 6:45 AM